Terlipressin use guidline
Reading File
Searching PubMed
terlipressin hepatorenal syndrome variceal bleeding
Finding Sources
Reading Article
PMID: 40207491
Reading File
Finding Sources
Searching the Web
terlipressin guidelines 2024 2025 hepatorenal syndrome variceal bleeding dosing
Reading File
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC11970894
I now have comprehensive information from textbooks, guidelines (AASLD, EASL, APASL), and recent meta-analyses (2024-2025). Here is a full structured guideline summary:
Terlipressin - Clinical Guidelines
1. Pharmacology Overview
Terlipressin (triglycyl-lysine-vasopressin) is a synthetic vasopressin V1a receptor agonist that acts preferentially on the splanchnic vascular bed. It causes splanchnic vasoconstriction, reduces portal pressure, and increases effective arterial blood volume and mean arterial pressure (MAP). This corrects the relative arterial underfilling that drives hepatorenal syndrome (HRS) and contributes to variceal bleeding. It was FDA-approved for HRS-AKI in September 2022 (brand name Terlivaz).
2. Approved Clinical Indications
A. Hepatorenal Syndrome (HRS-AKI) - Primary indication
B. Acute Variceal Bleeding (AVB) - Esophageal/gastric varices
C. Septic Shock (off-label/adjunctive in some regions)
3. Indication 1: Hepatorenal Syndrome (HRS-AKI)
Diagnostic Criteria (International Club of Ascites, 2015)
HRS-AKI is defined as:
- Cirrhosis with ascites
- Stage 2 or 3 AKI (serum creatinine rise ≥0.3 mg/dL in 48h, OR ≥50% rise from baseline within 7 days)
- No response to 2 days of diuretic withdrawal + volume expansion with albumin (1 g/kg/day, max 100 g/day)
- Absence of shock, recent nephrotoxic drug use, or signs of structural kidney injury (proteinuria <0.5 g/day, no hematuria, normal renal imaging)
Guideline Recommendations
| Guideline | Recommendation |
|---|---|
| AASLD 2021 | Terlipressin + albumin as first-line; target MAP rise ≥10 mmHg or creatinine decrease ≥25% in first 48h |
| EASL 2018/2022 | Terlipressin + albumin first-line for HRS-AKI; alternative: norepinephrine (ICU setting) or midodrine + octreotide (if terlipressin unavailable) |
| APASL | Terlipressin recommended as first-line |
| NICE (UK) | Recommended with albumin for HRS-1 |
Dosing - HRS-AKI
| Phase | Dose |
|---|---|
| Initial | 0.5-1 mg IV bolus every 4-6 hours |
| If no response at 48h (creatinine not decreased ≥25%) | Increase to 2 mg IV every 4-6 hours |
| Maximum | 12 mg/day |
| Duration | Up to 14 days (or until HRS reversal, transplant, or non-response) |
Continuous infusion alternative (preferred in some centers for better tolerability):
- 2 mg/24h, titrated to 12 mg/24h - recent evidence shows CTI improves tolerability and efficacy vs. bolus
Co-administration: Albumin (20-40 g/day)
- Current evidence (2025 meta-analysis, PMID 40207491) shows terlipressin + albumin significantly reduces HRS reversal failure (RR 0.64, 95% CI 0.53-0.78, P<0.00001)
- Note: Albumin dose should be individualized; routine high-dose albumin may increase risk of pulmonary edema
Response Criteria & Stopping Rules
- Treat if: serum creatinine decreases ≥25% by 48h
- Stop if: no response after dose escalation to 2 mg every 4-6h by day 3-5
- Stop if: creatinine >5 mg/dL (unlikely to benefit per FDA label)
- HRS reversal = two consecutive serum creatinine readings ≤1.5 mg/dL (or baseline)
4. Indication 2: Acute Variceal Bleeding (AVB)
Guideline Recommendations (AASLD, EASL, Baveno VII, APASL 2025)
Start IMMEDIATELY when variceal bleeding is suspected - even before endoscopy.
| Guideline | Dosing |
|---|---|
| AASLD | 2 mg IV bolus every 4-6h for first 24-48h, then 1 mg every 4-6h |
| EASL / Baveno VII | 2 mg IV bolus every 4h for first 48h, then 1 mg every 4h |
| GGC/UK (2024) | 2 mg IV bolus, then 2 mg every 4-6 hours until bleeding controlled, up to 48h |
Duration: 2-5 days (up to 5 days per most guidelines)
Combination therapy:
- Terlipressin + endoscopic variceal ligation (EVL) = standard of care for esophageal varices
- Terlipressin + N-butyl cyanoacrylate injection for gastric varices
- Add antibiotics (ceftriaxone 1g/24h x 7 days OR co-amoxiclav if allergy) - reduces mortality
Note: Recent APASL 2025 guidelines endorse abbreviated vasoactive drug courses (with similar outcomes), and support low-dose continuous infusion as an alternative to bolus.
5. Contraindications
Absolute
- Pregnancy (category X - causes uterine contractions)
- Coronary artery disease / recent ACS / unstable angina
- Peripheral vascular disease (significant)
- Mesenteric ischemia or bowel ischemia
- Cardiac arrhythmias (especially bradyarrhythmias)
- Respiratory failure or hypoxia at baseline
Relative / Cautions
- Hyponatremia (serum Na <130 mEq/L) - monitor closely
- Septic shock (hemodynamic instability)
- Creatinine >5 mg/dL in HRS (very unlikely to benefit)
- Recent liver transplant (may cause graft ischemia)
6. Adverse Effects
| Adverse Effect | Frequency | Notes |
|---|---|---|
| Abdominal pain/cramps | Common | V1a-mediated gut contraction |
| Diarrhea | Common | |
| Bradycardia | Common | |
| Hypertension | Common | |
| Peripheral ischemia (fingers, toes) | 5-10% | Ischemic necrosis possible |
| Pulmonary edema / respiratory failure | 5-10% | Most serious - monitor closely |
| Hyponatremia | ~10-15% | SIADH-like effect |
| Skin necrosis (injection site) | Rare |
Key 2024 safety data (PMID 39298544): Systematic review confirms hyponatremia, cardiovascular events, and respiratory complications as the most clinically significant adverse events. Risk of respiratory failure is mitigated by early initiation (before oliguria develops) and careful albumin titration.
7. Monitoring During Treatment
- Serum creatinine every 24-48h (HRS)
- Serum electrolytes (Na, K) daily
- Fluid balance and body weight daily
- O2 saturation / respiratory status - watch for pulmonary edema
- ECG - baseline and if symptoms
- MAP - target rise of ≥10 mmHg
- Peripheral perfusion - skin color, temperature of extremities
8. Position vs. Alternatives (HRS-AKI)
| Agent | Role |
|---|---|
| Terlipressin + albumin | First-line (worldwide); FDA-approved in USA since 2022 |
| Norepinephrine + albumin | Equally effective (2024 meta-analyses PMID 38285703, 38460713); preferred in ICU where terlipressin unavailable |
| Midodrine + octreotide + albumin | Less effective; used when terlipressin and NE unavailable |
| TIPS | Second-line if refractory; better for ascites control |
| Liver transplantation | Definitive cure; terlipressin used as a bridge |
| RRT/dialysis | Not a treatment for HRS; bridge to transplant |
2024-2025 meta-analysis evidence:
- Terlipressin vs. norepinephrine: comparable efficacy for HRS reversal and mortality (PMID 38285703, 38460713)
- Terlipressin + albumin: 36% reduction in HRS reversal failure vs. albumin alone (PMID 40207491, 2025)
9. Special Situations
Patients with Hyponatremia (Na <130 mEq/L)
- Use with caution; terlipressin can worsen hyponatremia (SIADH-like antidiuretic effect via V2 receptors)
- Monitor sodium daily; correct slowly
Patients with Cirrhosis + Sepsis (SBP precipitating HRS)
- Treat underlying infection aggressively
- Terlipressin can be started alongside antibiotics + albumin
Pre-transplant Bridging
- Terlipressin improves transplant candidacy by reversing HRS creatinine
- However, FDA label warns that terlipressin-induced adverse events may render a patient ineligible for transplant
HRS-NAKI (Type 2 HRS)
- Terlipressin not routinely recommended (weaker evidence); discuss case-by-case
10. Quick Reference Summary
HRS-AKI: Start terlipressin 0.5-1 mg IV bolus q4-6h + albumin 20-40 g/day. Escalate to 2 mg q4-6h if no 25% creatinine drop by 48h. Treat up to 14 days. Stop if creatinine >5 mg/dL or refractory.
Variceal Bleeding: Start 2 mg IV bolus at presentation (pre-endoscopy). Then 1-2 mg q4-6h for 2-5 days. Combine with EVL and prophylactic antibiotics.
Always monitor: Respiratory status, Na, creatinine, peripheral ischemia, cardiac rhythm.
Sources: AASLD 2021, EASL 2022, Baveno VII Consensus, APASL 2025, Brenner & Rector's The Kidney (9780323532655), Sleisenger & Fordtran's GI and Liver Disease (9780323609623), Yamada's Textbook of Gastroenterology; supported by 2024-2025 meta-analyses (PMIDs: 40207491, 39295934, 38285703, 38460713, 39298544).
This is a shared conversation. Sign in to Orris to start your own chat.